Search results for "SARS"

showing 10 items of 1372 documents

Seroprevalence of SARs-CoV-2 among the staff and patients of a French cancer centre after first lockdown: the canSEROcov study

2021

Abstract Background In view of the potential gravity of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection for patients with cancer, epidemiological data are vital to assess virus circulation among patients and staff of cancer centres. We performed a prospective study to investigate seroprevalence of SARS-CoV-2 antibodies among staff and patients with cancer at a large cancer centre, at the end of the period of first national lockdown in France and to determine factors associated with the risk of SARS-CoV-2 infection. Methods After the first lockdown, all medical and non-medical staff, as well as all patients attending the medical oncology department were invited to unde…

0301 basic medicineMaleCancer ResearchSerology0302 clinical medicineHygieneSeroepidemiologic StudiesEpidemiologyMedicineProspective cohort studyChildmedia_commonOriginal ResearchAged 80 and overserodiagnosisseroprevalenceSocial distanceMiddle AgedSerologyOncology030220 oncology & carcinogenesisChild PreschoolCarrier StateFemaleFrancemedicine.symptomAdultmedicine.medical_specialtyAdolescentmedia_common.quotation_subjectHealth PersonnelSARS-COV-2Cancer Care FacilitiesAsymptomaticCOVID-19 Serological Testingstaff03 medical and health sciencesYoung AdultSeroprevalenceHumansAntibodyAgedbusiness.industryhealthcare workersCancerCOVID-19cancer centerCancer patientsmedicine.diseasePersonnel Hospital030104 developmental biologyFamily medicinebusinessEuropean Journal of Cancer
researchProduct

Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 pandemic. risk analysis from the PSO-BIO-COVI…

2021

Background The susceptibility of patients with chronic plaque psoriasis and the risks or benefits related to the use of biological therapies for COVID-19 are unknown. Few data about prevalence, clinical course and outcomes of COVID-19 among psoriatic patients were reported. The aims of this study were 1) to assess the prevalence and severity of COVID-19 in psoriatic patients treated with biologic agents during the first phase of the emergency (22 February to 22 April 2020) in Italy, and 2) to report the clinical outcomes of patients who have been exposed to individuals with confirmed SARS-CoV-2 infection. Methods Patients with moderate-to-severe chronic plaque psoriasis, aged ≥18 years and …

0301 basic medicineMaleClinical BiochemistryDiseaseCohort Studies0302 clinical medicineDrug DiscoveryReceptors80 and overMedicineAged 80 and overeducation.field_of_studyIncidence (epidemiology)IncidenceInterleukin-17psoriasisMiddle Ageddermatologysars-CoV-2Italybiological therapy030220 oncology & carcinogenesisCohortBiological ProductCOVID-19; biological therapy; dermatology; psoriasis; sars-CoV-2FemaleSettore MED/35 - MALATTIE CUTANEE E VENEREEbiological therapy; COVID-19; dermatology; psoriasis; sars-CoV-2; Adult; Aged; Aged 80 and over; Biological Products; Biological Therapy; COVID-19; Chronic Disease; Cohort Studies; Female; Humans; Incidence; Interleukin-17; Italy; Male; Middle Aged; Pandemics; Psoriasis; Receptors Interleukin; Risk Assessment; Tumor Necrosis Factor-alpha; Young AdultCohort studyHumanAdultmedicine.medical_specialtyPopulationRisk AssessmentCOVID-19; psoriasis; biological therapy; dermatology; sars-CoV-203 medical and health sciencesYoung AdultSettore MED/35Internal medicinePsoriasisPsoriasis.HumanseducationPandemicsAgedPharmacologyPsoriasiBiological ProductsPandemicbiological therapy; COVID-19; dermatology; psoriasis; sars-CoV-2business.industryTumor Necrosis Factor-alphaCOVID-19Receptors InterleukinBiological productInterleukinmedicine.diseaseClinical trial030104 developmental biologyChronic DiseaseCOVID-19; SARS-CoV-2; biological therapy; dermatology; psoriasisCohort Studiebusiness
researchProduct

Short‐term neuropsychiatric outcomes and quality of life in COVID‐19 survivors

2021

BACKGROUND: The general medical impacts of coronavirus (COVID-19) are increasingly appreciated. However, its impact on neurocognitive, psychiatric health and quality of life (QoL) in survivors after the acute phase is poorly understood. We aimed to evaluate neurocognitive function, psychiatric symptoms, and QoL in COVID-19 survivors shortly after hospital discharge. METHODS: This was a cross-sectional analysis of a prospective study of hospitalised COVID-19 survivors followed-up for 2 months after discharge. A battery of standardised instruments evaluating neurocognitive function, psychiatric morbidity, and QoL (mental and physical components) was administered by telephone. RESULTS: Of the …

0301 basic medicineMalePediatrics030204 cardiovascular system & hematologyAnxietySevere Acute Respiratory SyndromeStress Disorders Post-Traumatic0302 clinical medicineCognitionQuality of lifeOutcome Assessment Health CareMedicineVerbal fluency testProspective StudiesSurvivorsProspective cohort studyLetter to the EditorDepression (differential diagnoses)Aged 80 and overPsychiatryDepressionMiddle AgedsequelaehumanitiesMemory Short-TermneurocognitiveAnxietyFemaleOriginal Articlemedicine.symptomAdultmedicine.medical_specialtypsychiatric morbidity03 medical and health sciencesYoung AdultSex FactorsCOVID‐19Internal MedicineHumansAgedMemory Disordersbusiness.industryWorking memorySARS-CoV-2COVID-19Original Articles030104 developmental biologyCross-Sectional Studiesquality of lifeDeliriumbusinessCognition DisordersNeurocognitiveCOVID-19 neurocognitive psychiatric morbidity quality of life sequelaeJournal of Internal Medicine
researchProduct

Proper assignation of reactivation in a COVID-19 recurrence initially interpreted as a reinfection

2021

A 77-year-old-male (Case R) who had had a previous diagnosis of mild COVID-19 episode, was hospitalized 35 days later. On Day 23 post-admission, he developed a second COVID-19 episode, now severe, and finally died. Initially, Case R COVID-19 recurrence was interpreted as a reinfection due to the exposure to a SARS-CoV-2 RT-PCR-positive room-mate. However, whole-genome-sequencing indicated that case R recurrence corresponded to a reactivation of the strain involved in his first episode. Case R reactivation had major consequences, leading to a more severe episode, and causing a subsequent transmission to another two hospitalized patients, one of them with fatal outcome.

0301 basic medicineMalePediatricsmedicine.medical_specialty2019-20 coronavirus outbreakFatal outcomeCoronavirus disease 2019 (COVID-19)Hospitalized patientsSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Antibodies Viral03 medical and health sciences0302 clinical medicineNosocomial transmissionRecurrencemedicineImmunology and AllergyHumans030212 general & internal medicineAgedFirst episodeWhole Genome Sequencingbusiness.industrySARS-CoV-2Nosocomial transmissionBrief ReportCOVID-19Reactivation030104 developmental biologyInfectious DiseasesAcademicSubjects/MED00290ReinfectionbusinessWGS
researchProduct

Field evaluation of a rapid antigen test (Panbio™ COVID-19 Ag Rapid Test Device) for COVID-19 diagnosis in primary healthcare centres.

2021

Abstract Objectives To our knowledge no previous study has assessed the performance of a rapid antigen diagnostic immunoassay (RAD) conducted at the point of care (POC). We evaluated the Panbio™ COVID-19 Ag Rapid Test Device for diagnosis of coronavirus 2019 disease (COVID-19) in symptomatic patients (n = 412) attending primary healthcare centres. Methods RAD was performed immediately after sampling following the manufacturer's instructions (reading at 15 min). RT-PCRs were carried out within 24 h of specimen collection. Samples displaying discordant results were processed for culture in Vero E6 cells. Presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in cell cultures…

0301 basic medicineMaleRapid antigen detection test (RAD)medicine.disease_causeAmbulatory Care Facilities0302 clinical medicineNasopharynx030212 general & internal medicineChildAntigens ViralCoronavirusAged 80 and overImmunoassaymedicine.diagnostic_testGeneral MedicineMiddle AgedEarly diagnosisResearch NoteInfectious DiseasesSpecimen collectionRapid antigen testPoint-of-Care TestingCOVID-19 Nucleic Acid TestingChild PreschoolFemaleMicrobiology (medical)Adultmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)AdolescentPoint-of-care testing030106 microbiologySensitivity and SpecificityCOVID-19 Serological Testing03 medical and health sciencesYoung AdultAntigenInternal medicinemedicineHumansPoint of careAgedbusiness.industrySARS-CoV-2COVID-19InfantImmunoassayReagent Kits DiagnosticbusinessPrimary healthcare centreClinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
researchProduct

Genetic justification of severe COVID-19 using a rigorous algorithm

2021

Recent studies suggest excessive complement activation in severe coronavirus disease-19 (COVID-19). The latter shares common characteristics with complement-mediated thrombotic microangiopathy (TMA). We hypothesized that genetic susceptibility would be evident in patients with severe COVID-19 (similar to TMA) and associated with disease severity. We analyzed genetic and clinical data from 97 patients hospitalized for COVID-19. Through targeted next-generation-sequencing we found an ADAMTS13 variant in 49 patients, along with two risk factor variants (C3, 21 patients; CFH,34 patients). 31 (32%) patients had a combination of these, which was independently associated with ICU hospitalization (…

0301 basic medicineMaleThrombomodulinSeverity of Illness Index0302 clinical medicineRisk FactorsImmunology and AllergyMedicineComplement ActivationRigorous algorithmmedicine.diagnostic_testHigh-Throughput Nucleotide SequencingComplement C3EculizumabEculizumabMiddle AgedHospitalizationSettore ICAR/09 - Tecnica Delle CostruzioniIntensive Care UnitsFactor HComplement Factor HFemaleAlgorithmsmedicine.drugmedicine.medical_specialtyThrombotic microangiopathyCritical CareImmunologyComplementADAMTS13 Protein03 medical and health sciencesInternal medicineFull Length ArticleSeverity of illnessGenetic predispositionGenetic susceptibilityHumansGenetic Predisposition to DiseaseGenetic TestingRisk factorGenetic testingAgedbusiness.industryThrombotic MicroangiopathiesCOVID-19medicine.diseaseComplement system030104 developmental biologySARS-CoV2business030215 immunologyClinical Immunology (Orlando, Fla.)
researchProduct

Inference of SARS-CoV-2 spike-binding neutralizing antibody titers in sera from hospitalized COVID-19 patients by using commercial enzyme and chemilu…

2021

medRxiv: https://doi.org/10.1101/2020.09.07.20188151

0301 basic medicineMalevirusesAntibodies ViralImmunoglobulin Glaw.invention0302 clinical medicineMedical microbiologylawMedicine030212 general & internal medicineNeutralizing antibodyImmunoassaychemistry.chemical_classificationmedicine.diagnostic_testbiologyAntibody titerGeneral MedicineMiddle AgedHospitalizationTiterInfectious DiseasesSpike Glycoprotein CoronavirusOriginal ArticleFemaleAntibodyMicrobiology (medical)Adultmedicine.medical_specialtySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)030106 microbiologyNeutralizing antibodiesSensitivity and SpecificityVirusCOVID-19 Serological Testing03 medical and health sciencesEnzyme-linked immunosorbent assayNeutralization TestsHumansAgedChemiluminescenceSARS-CoV-2business.industryfungiCOVID-19Antibodies NeutralizingVirologyChemiluminescent immunoassaysKineticsEnzymechemistryImmunoassayImmunoglobulin Gbiology.proteinbusiness
researchProduct

Evaluation of Anti-SARS-Cov-2 S-RBD IgG Antibodies after COVID-19 mRNA BNT162b2 Vaccine

2021

(1) Background: The evaluation of anti-spike protein receptor-binding domain (S-RBD) antibodies represents a useful tool to estimate the individual protection against Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2) infection

0301 basic medicineMedicine (General)Coronavirus disease 2019 (COVID-19)Chemiluminescence immunoassayvirusesSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Clinical BiochemistryAsymptomaticArticleAntibodies03 medical and health sciencesR5-9200302 clinical medicineMedicineKineticMessenger RNAbiologySARS-CoV-2business.industryVaccinationvirus diseasesCOVID-19spikeVaccination030104 developmental biologyAntibody response030220 oncology & carcinogenesisImmunologybiology.proteinmedicine.symptomAntibodybusinessImmunosurvellianceVaccineS-RBD IgGDiagnostics
researchProduct

miR-1207-5p Can Contribute to Dysregulation of Inflammatory Response in COVID-19 via Targeting SARS-CoV-2 RNA

2020

The present study focuses on the role of human miRNAs in SARS-CoV-2 infection. An extensive analysis of human miRNA binding sites on the viral genome led to the identification of miR-1207-5p as potential regulator of the viral Spike protein. It is known that exogenous RNA can compete for miRNA targets of endogenous mRNAs leading to their overexpression. Our results suggest that SARS-CoV-2 virus can act as an exogenous competing RNA, facilitating the over-expression of its endogenous targets. Transcriptomic analysis of human alveolar and bronchial epithelial cells confirmed that the CSF1 gene, a known target of miR-1207-5p, is over-expressed following SARS-CoV-2 infection. CSF1 enhances macr…

0301 basic medicineMicrobiology (medical)030106 microbiologyImmunologylcsh:QR1-502miRNA target predictionInflammationMiRNA bindingEndogenyBiologyMicrobiologylcsh:MicrobiologyVirusTranscriptome03 medical and health sciencesmacrophage recruitmentmicroRNAmedicinecompeting RNAsGenemicroRNA regulatory networkSARS-CoV-2fungiRNAinflammatory responseCell biology030104 developmental biologyInfectious Diseasesmedicine.symptomFrontiers in Cellular and Infection Microbiology
researchProduct

The usefulness of NEWS2 at day 7 of hospitalization in predicting COVID-19 evolution and as an early endpoint in therapeutic trials

2021

Highlights • There is a need for reliable tools to predict the evolution of hospitalized patients suffering from COVID-19 • The likelihood of unfavourable evolution for patients hospitalized for COVID-19 with a National • Early Warning Score 2 (NEWS2) below 7 at Day 7 of hospitalization is nearly non-existent • Such a score could thus be used to allow earlier discharge of the patients and as a judgement criterion in therapeutic trials

0301 basic medicineMicrobiology (medical)2019-20 coronavirus outbreakmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)030106 microbiologyNEWS2Communicable DiseasesArticle03 medical and health sciences0302 clinical medicineMedicineHumans030212 general & internal medicineIntensive care medicineUnfavourable eventAgedbusiness.industrySARS-CoV-2COVID-19Therapeutic trialCoronavirusHospitalizationInfectious DiseasesItalySARS-CoV2businessPredictionThe Journal of Infection
researchProduct